Sodium-glucose cotransporter-2 inhibitors

Suissa, K., Schneeweiss, S., Douros, A., Yin, H., Patorno, E., & Azoulay, L. (2022). Obesity as a modifier of the cardiovascular effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes. Diabetes Res Clin Pract, 192, 110094. http://doi.org/10.1016/j.diabres.2022.110094

View

Eroglu, T. E., Coronel, R., Zuurbier, C. J., Blom, M., de Boer, A., & Souverein, P. C. (2022). Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus. Eur Heart J Cardiovasc Pharmacother. http://doi.org/10.1093/ehjcvp/pvac043

View

Pradhan, R., Patorno, E., Tesfaye, H., Schneeweiss, S., Yin, H., Franklin, J., et al. (2022). Glucagon-Like Peptide-1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients With Type 2 Diabetes: Multisite Population-Based Cohort Study. Am J Epidemiol. http://doi.org/10.1093/aje/kwac021

View